DelveInsight’s, “Spinocerebellar Ataxias Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Spinocerebellar Ataxias pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight’s comprehensive Spinocerebellar Ataxias Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Spinocerebellar Ataxias Pipeline Outlook Report

Key Takeaways from the Spinocerebellar Ataxias Pipeline Report

• On 04 November 2025, Biohaven Pharmaceuticals Inc. conducted a study is to compare the efficacy of Troriluzole (200 mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).
• On 03 November 2025, Quince Therapeutics S.p.A announced a IEDAT-05-2024 study aims to provide EryDex (dexamethasone sodium phosphate encapsulated into autologous erythrocytes) treatment to patients who complete the full study treatment period (including those receiving placebo) in the IEDAT-04-2022 (NEAT) study, who complete the study assessments, do not present safety contraindications to continuation of treatment, and provide informed consent. The open-label extension (OLE) treatment period will be 12 months.
• DelveInsight’s Spinocerebellar Ataxias Pipeline analysis depicts a robust space with 8+ active players working to develop 10+ pipeline treatment therapies.
• The leading Spinocerebellar Ataxias Companies such as Biohaven Pharmaceuticals, Inc., Steminent US, Inc., Vico Therapeutics B.V., Arrowhead Pharmaceuticals, Neurolixis, Latus Bio, AAV-CB and others.
• Promising Spinocerebellar Ataxias Pipeline Therapies such as Troriluzole, KPS-037, VO659, Varenicline, N-Acetyl-L-Leucine, DT-216P2, MIB-626, Omaveloxolone, Vatiquinone, and others.

Access DelveInsight’s in-depth Spinocerebellar Ataxias Pipeline Analysis for a closer look at promising breakthroughs @ Spinocerebellar Ataxias Clinical Trials and Studies

Spinocerebellar Ataxias Overview

Spinocerebellar ataxia (SCA) is a rare, progressive, inherited neurodegenerative disorder that primarily affects the cerebellum but can involve other parts of the central nervous system. It is classified into over 40 subtypes based on genetic loci, with common types including SCA1, SCA2, SCA3, and SCA6, which account for the majority of cases. SCA is characterized by the loss of voluntary muscle coordination, impacting gait, speech, and eye movement. Although primarily associated with the cerebellum and spinal cord, SCA

Spinocerebellar Ataxias Emerging Drugs Profile

• Troriluzole: Biohaven Pharmaceuticals, Inc.

Troriluzole is a New Chemical Entity (NCE) and third-generation novel prodrug that modulates glutamate, the most abundant excitatory neurotransmitter in the human body. The primary mode of action of troriluzole is reducing synaptic levels of glutamate. Troriluzole increases glutamate uptake from the synapse, by augmenting the expression and function of excitatory amino acid transporters located on glial cells that play a key role in clearing glutamate from the synapse. Troriluzole has the potential to be developed in a number of other diseases associated with excessive glutamate. In February 2025, Biohaven Ltd. announced that the US Food and Drug Administration (FDA) has accepted for review the Company’s New Drug Application for troriluzole for the treatment of adult patients with spinocerebellar ataxia.

• Stemchymal: Steminent US, Inc.

Stemchymal is an allogeneic stem cell therapy, meaning it uses stem cells obtained from one patient to treat another. The mesenchymal stem cells (MSCs) used to create Stemchymal are isolated from the adipose, or fatty, tissue of healthy individuals. Once isolated from this primary tissue using a unique cell processing system, the MSCs are administered to recipients by intravenous (IV) infusion. As MSCs display low immunogenicity, they are less likely to cause an immune reaction in patients receiving treatment. These cells have also displayed therapeutic effects in vivo, with infusion shown to partially restore motor function in SCA mouse models. Stemchymal has also been granted orphan drug designation in Japan. Currently, the drug is in Phase II stage of its development for the treatment of Spinocerebellar Ataxias.

• VO659: Vico Therapeutics B. V.

VO659 is the first clinical candidate directly targeting the CAG repeat expansion, the mutation that causes all polyglutamine diseases. VO659 is an ASO that directly targets the CAG repeat expansion and reduces mutant protein in an allele preferential manner. VO659 is designed to bind directly to the CAG repeats, sterically block translation and reduce the mutant protein. The CAG repeat expansion causes nine polyQ diseases, including Huntington’s disease and various forms of spinocerebellar ataxia. By focusing on this common mutation, VO659 has the potential to address multiple polyQ disorders with a single therapy. VO659 employs an innovative allele-preferential approach. This precision targeting allows us to reduce the mutant protein while preserving essential normal gene function – a crucial advancement in treating these complex disorders like SCA. Currently, the drug is in Phase I/II stage of its development for the treatment of Spinocerebellar Ataxias.

The Spinocerebellar Ataxias Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Spinocerebellar Ataxias with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinocerebellar Ataxias Treatment.
• Spinocerebellar Ataxias Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Spinocerebellar Ataxias Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinocerebellar Ataxias market

Explore groundbreaking therapies and clinical trials in the Spinocerebellar Ataxias Pipeline. Access DelveInsight’s detailed report now! @ New Spinocerebellar Ataxias Drugs

Spinocerebellar Ataxias Companies

Biohaven Pharmaceuticals, Inc., Steminent US, Inc., Vico Therapeutics B.V., Arrowhead Pharmaceuticals, Neurolixis, Latus Bio, AAV-CB and others.

Spinocerebellar Ataxias pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Spinocerebellar Ataxias Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key developments @ Spinocerebellar Ataxias Market Drivers and Barriers, and Future Perspectives

Scope of the Spinocerebellar Ataxias Pipeline Report

• Coverage- Global
• Spinocerebellar Ataxias Companies- Biohaven Pharmaceuticals, Inc., Steminent US, Inc., Vico Therapeutics B.V., Arrowhead Pharmaceuticals, Neurolixis, Latus Bio, AAV-CB and others.
• Spinocerebellar Ataxias Pipeline Therapies- Troriluzole, KPS-037, VO659, Varenicline, N-Acetyl-L-Leucine, DT-216P2, MIB-626, Omaveloxolone, Vatiquinone, and others.
• Spinocerebellar Ataxias Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Spinocerebellar Ataxias Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight’s exclusive Spinocerebellar Ataxias Pipeline Report—access it now! @ Spinocerebellar Ataxias Emerging Drugs and Major Companies

Table of Content

1. Introduction
2. Executive Summary
3. Spinocerebellar Ataxias: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Spinocerebellar Ataxias– DelveInsight’s Analytical Perspective
7. Late Stage Products (Registration)
8. Troriluzole: Biohaven Pharmaceuticals, Inc.
9. Mid Stage Products (Phase II)
10. Stemchymal: Steminent US, Inc.
11. Early Stage Products (Phase I/II)
12. VO659: Vico Therapeutics B. V.
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Spinocerebellar Ataxias Key Companies
17. Spinocerebellar Ataxias Key Products
18. Spinocerebellar Ataxias- Unmet Needs
19. Spinocerebellar Ataxias- Market Drivers and Barriers
20. Spinocerebellar Ataxias- Future Perspectives and Conclusion
21. Spinocerebellar Ataxias Analyst Views
22. Spinocerebellar Ataxias Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/spinocerebellar-ataxias-pipeline-insight